4th Quarter - Report

TARPLIN, DOWNS & YOUNG, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION)

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1781 - Payment Commission Data Act of 2019 H.R. 269 - PAHPA Reauthorization and Advancing Innovation Act of 2019 S. 97 - Affordable and Safe Prescription Drug Importation Act S. 1416 - Affordable Prescriptions For Patients Act of 2019 S. 1895 - Lower Health Care Costs Act H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act H.R. 5333 - OTC Monograph Reform Act H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act H.R. 6800 - The Heroes Act H.R. 133 - Consolidated Appropriations Act, 2021 no specific bills, importation, supply chain integrity, 304b, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, drug pricing, insulin, international reference pricing

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 6074 (116th), S. 1416 (116th), S. 97 (116th), H.R. 1781 (116th), S. 2543 (116th), H.R. 3 (116th), H.R. 5333 (116th), H.R. 6201 (116th), H.R. 269 (116th), H.R. 133 (116th), S. 3548 (116th), H.R. 6800 (116th), S. 1895 (116th)

Medicare/Medicaid MMM

no specific bills, Medicare Reimbursement, Medicaid Rebate, Medicaid Coverage and Reimbursement, quality indicators, coding, oncology, CMMI, Part B, ASP, insulin access, vaccines, flu, prescription drug access and affordability, transparency, international reference pricing, Medicaid Value Based Payment rule H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 H.R. 133 - Consolidated Appropriations Act, 2021

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

LobbyistCovered position, as disclosed
RAISSA H DOWNS Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
MICHELLE P EASTON Chief Health Counsel, Sen. Cmte. on Finance; Staff Dir., Senate Aging Cmte.; Leg. Asst., Congressman Billy Tauzin
CHARLOTTE SPEARS IVANCIC Legislative Counsel, Senator Jim DeMint; Health Counsel, Majority Leader Bill Frist; Counsel and Budget Analyst, House Budget Committee; Asst. to the Speaker for Policy, Speaker John Boehner
ELIZABETH T MURRAY Senior Policy Advisor, Democratic Whip Steny Hoyer; Legislative Asst. for Rep. Mike Thompson, Rep. Bob Matsui, and Senator Bob Graham
EMILY H MURRY Staff Dir., Sub. Cmte. on Health, W&M Cmte; Sr. Policy Advisor, Majority Leader McCarthy; Policy Advisor, Majority Whip McCarthy; Professional Staff, Republican Study Cmte.; Leg. Aid, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price
PAMELA SMITH Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun
JENNIFER B YOUNG Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2543 (116th), H.R. 133 (116th), H.R. 3 (116th), S. 3129 (116th), S. 3013 (116th)

Budget/Appropriations BUD

deficit reduction, debt ceiling, appropriations, biodefense H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 1865 - Further Consolidated Appropriations Act, 2020 H.R. 3055 - Further Continuing Appropriations Act, 2020, and Further Health Extenders Act H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 133 - Consolidated Appropriations Act, 2021

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 133 (116th), H.R. 3055 (116th), H.R. 1865 (116th), H.R. 8337 (116th), H.R. 4378 (116th)

Copyright/Patent/Trademark CPT

Patent reform

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA)

Taxation/Internal Revenue Code TAX

orphan drug tax credit

Foreign entity interest: "As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Form LD-1, has an interest in the issues lobbied."

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); SENATE

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.